Table 3 Pathological results and tumor response to neoadjuvant treatment (N = 34)b
| Â | No. (%) |
|---|---|
ypT | |
 0 | 9 (26.4) |
 1 | 0 (0) |
 2 | 5 (14.7) |
 3 | 17 (50.0) |
 4 | 3 (8.9) |
ypN | |
 0 | 28 (82.4) |
 1 | 5 (14.7) |
 2 | 1 (2.9) |
Median number of resected nodesa | 11 (3–26) |
Median number of involved nodesa | 0 (0–6) |
Lymph node with extranodal involvement | 4 (11.7) |
Lymphovascular invasion | |
 Yes | 5 (14.7) |
 No | 29 (85.3) |
Perineural invasion | |
 Yes | 2 (5.9) |
 No | 32 (94.1) |
Tumor differentiation | |
 Well | 2 (5.9) |
 Moderately | 28 (82.4) |
 Poorly | 4 (11.7) |
Resection margin (CRM) | |
 Negative | 31 (91.2) |
 Positive | 3 (8.8) |
Pathologic complete response | |
 Yes | 9 (26.4) |
 No | 25 (73.6) |
Tumor regression grade | |
 0 | 9 (26.4) |
 1 | 11 (32.4) |
 2 | 7 (20.6) |
 3 | 7 (20.6) |
ypT0-2 vs. ypT3-4 | |
 ypT0-2 | 14 (41.2) |
 ypT3-4 | 20 (58.8) |
Pathologic T stage | |
 Downstaging | 24 (70.6) |
 Stable | 10 (29.4) |
 Progressive | 0 (0) |
Pathologic N stage | |
 Downstaging | 31 (91.2) |
 Stable | 3 (8.8) |
 Progressive | 0 (0) |
Pathologic TN stage | |
 Downstaging | 29 (85.3) |
 Stable | 5 (14.7) |
 Progressive | 0 (0) |